STOCK TITAN

Acme United Q3 net income rises 80% to $3.4M

Tariff refunds contributed approximately 690 basis points to third-quarter gross margin, partly offset by 310 basis points from DMT closure costs.

(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Acme United Corporation reported third-quarter 2026 net sales of $58.0 million, up 18% from $49.1 million a year earlier; comparable sales excluding My Medic rose 10%. Net income increased 80% to $3.4 million, and diluted earnings per share rose 74% to $0.80. For the first nine months, sales were $173.0 million, up 16%, and net income was $9.5 million, up 14%.

Third-quarter gross margin was 45.3%, versus 39.1% a year earlier. The $6.0 million tariff refund included $4.0 million recognized as a reduction of cost of goods sold and $2.0 million recorded as an accrued liability as of September 30, 2026; the refund contributed approximately 690 basis points to gross margin, partly offset by approximately 310 basis points from $1.8 million of DMT facility closure costs.

Bank debt less cash was $29.7 million as of September 30, 2026, compared with $23.1 million a year earlier. Acme United generated approximately $13.8 million in free cash flow during the twelve months ended September 30, 2026, including $6.0 million in tariff refunds. The company plans to close its DMT plant in Massachusetts later this year; annual savings from the closure are expected to be more than $1.0 million in 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointThird-quarter net sales rose 18%; net income increased 80% to $3.4 million.

Negative

  • Moderate pointDMT closure costs reduced third-quarter gross margin by approximately 310 basis points.

Filing Explained

The release says My Medic contributed to sales growth but had minimal earnings impact through the first nine months; Acme says the business historically earns most of its profit in the fourth quarter and expects that seasonal pattern to continue.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net sales $58.0 million Third quarter 2026; up 18% from the same period in 2025.
Comparable sales increase excluding My Medic 10% Third quarter 2026.
Net income $3.4 million Third quarter 2026; up 80% from the same period in 2025.
Diluted earnings per share $0.80 Third quarter 2026; up 74% from the same period in 2025.
Gross margin 45.3% Third quarter 2026; 39.1% in the comparable period in 2025.
Tariff refund recognized as a reduction of cost of goods sold $4.0 million Third quarter 2026.
DMT facility closure costs $1.8 million Included in third-quarter 2026 cost of goods sold.
Bank debt less cash $29.7 million As of September 30, 2026; compared with $23.1 million as of September 30, 2025.
comparable three-month sales financial
"comparable three-month sales increased 10%"
gross margin financial
"Gross margin was 45.3% in the third quarter of 2026"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
accrued liability financial
"recorded as an accrued liability on the balance sheet"
An accrued liability is a cost a company has incurred and recorded in its accounts before the cash has been paid. It represents a present obligation for goods, services, wages, interest, taxes or other expenses that are recognized on the income statement and shown on the balance sheet (usually as a current liability) even though payment will occur later; recording accruals follows the accounting principle of matching expenses to the period when they were incurred, not when cash changes hands.
free cash flow financial
"generated approximately $13.8 million in free cash flow"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
bank debt less cash financial
"bank debt less cash as of September 30, 2026"
Net sales $58.0 million 18% increase from $49.1 million in the same period in 2025
Net income $3.4 million 80% increase from $1.9 million in the same period in 2025
Diluted earnings per share $0.80 74% increase from $0.46 in the same period in 2025
Gross margin 45.3% 39.1% in the comparable period in 2025
Guidance

Annual savings from the DMT plant closure are expected to be more than $1.0 million in 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were ACU's third-quarter 2026 sales and earnings?

Acme United reported $58.0 million in net sales, $3.4 million in net income, and diluted earnings per share of $0.80. Compared with the same quarter in 2025, sales increased 18%, net income increased 80%, and diluted earnings per share increased 74%.

How did My Medic affect ACU's third-quarter results?

My Medic contributed to sales growth, but its seasonal nature meant it had minimal impact on earnings in the third quarter and the first nine months of 2026. Acme United said the business has historically generated most of its profitability in the fourth quarter and expected that pattern to continue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
false000000209800000020982026-10-272026-10-27

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): October 27, 2026

 

ACME UNITED CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Connecticut

001-07698

06-0236700

(State or other jurisdiction

of incorporation or organization)

(Commission file number)

(I.R.S. Employer

Identification No.)

1 Waterview Dr, Shelton, Connecticut

 

06484

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (203) 254-6060

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $2.50 par value per share

 

ACU

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On October 27, 2026, Acme United Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

 

Exhibit

Number

Description

99.1

Press release dated October 27, 2026.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ACME UNITED CORPORATION

 

By

/s/ Walter C. Johnsen

Walter C. Johnsen

Chairman and

Chief Executive Officer

Dated: October 27, 2026

By

/s/ Paul G. Driscoll

Paul G. Driscoll

Vice President and

Chief Financial Officer

Dated: October 27, 2026

 

 


Ex 99.1

 

ACME UNITED CORPORATION NEWS RELEASE

CONTACT: Paul G. Driscoll Acme United Corporation 1 Waterview Drive Shelton, CT 06484

Phone: (203) 254-6060

 

FOR IMMEDIATE RELEASE October 27, 2026

 

 

ACME UNITED REPORTS THIRD QUARTER 2026 NET SALES INCREASE OF 18%

 

SHELTON, CT – October 27, 2026 – Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended September 30, 2026, were $58.0 million compared to $49.1 million for the same period in 2025, an increase of 18%. Excluding sales resulting from the acquisition of the assets of My Medic on January 15, 2026, comparable three-month sales increased 10%. Net sales for the nine months ended September 30, 2026, were $173.0 million, compared to $149.0 million in the same period in 2025, an increase of 16%. Excluding My Medic sales, comparable nine-month sales increased 8%.

 

Net income was $3.4 million, or $0.80 per diluted share, for the quarter ended September 30, 2026, compared to $1.9 million, or $0.46 per diluted share, for the same period in 2025, an increase of 80% in net income and 74% in diluted earnings per share. Net income for the nine months ended September 30, 2026, was $9.5 million, or $2.29 per diluted share, compared to $8.3 million, or $2.03 per diluted share, for the same period in 2025, an increase of 14% in net income and 13% in diluted earnings per share.

 

Chairman and CEO, Walter C. Johnsen said, “We had record sales in the quarter, with growth in all our business units and internationally. Back-to-school sales were strong. The My Medic integration is progressing on plan, and we are beginning to receive retail and distribution commitments for its product lines next year.”

 

The Company applied for and received $6.0 million in IEEPA tariff refunds and in the third quarter of 2026, the Company recognized $4.0 million of the refund as a reduction of cost of goods sold. The remaining $2.0 million was recorded as an accrued liability on the balance sheet as of September 30, 2026. In the third quarter, the Company also recorded $1.0 million of variable compensation expense related to the refund, included in selling,

1

 


Ex 99.1

general and administrative expenses. Additionally, in the third quarter of 2026, cost of goods sold included $1.8 million of costs accrued in connection with the close of our DMT sharpening facility and the related move of production of the DMT products to more cost-effective facilities in Asia. Net income for the three- and nine-month periods ended September 30, 2026 also included approximately $0.4 million of tax benefits resulting from stock option exercises.

 

The My Medic business acquired in January 2026, sells tactical, trauma and emergency response products directly to consumers, contributed to sales growth but due to the seasonal nature of the My Medic business there was minimal impact on earnings in the third quarter and the first nine months of 2026. As a direct-to-consumer business, My Medic has historically generated the majority of its profitability in the fourth quarter and we expect this pattern to continue.

 

Mr. Johnsen continued, “Transportation and many raw materials are increasing in cost. We continue to address these issues by using new robotics in our plants, sourcing very competitively, and consolidating operations. Later this year, we plan to close our DMT plant in Massachusetts and shift production and fulfillment to other locations and offshore. The annual savings from the closure are expected to be more than $1.0 million in 2027.

 

Mr. Johnsen concluded, “Our balance sheet is strong, and we continue to look for acquisitions that fit our strategic criteria.”

 

For the third quarter of 2026, net sales in the U.S. segment increased 20% compared to the same period in 2025. For the nine months ended September 30, 2026, net sales in the U.S. segment increased 17% compared to the same period in 2025. The sales increases for the three- and nine-month periods were due to strong sales across all product lines and contribution from the acquisition of the My Medic business.

 

European net sales for the third quarter of 2026 increased 5% in U.S. dollars and 7% in local currency compared to the third quarter of 2025. Net sales for the nine months ended September 30, 2026, increased 20% in U.S. dollars and 15% in local currency compared to

2

 


Ex 99.1

the same period of 2025. The sales increases for the three- and nine-month periods were due primarily to higher ecommerce sales and contribution from the line of cutting and sharpening products acquired in Germany on October 1, 2025.

 

Net sales in Canada for the third quarter of 2026 increased 9% in U.S. dollars and 12% in local currency compared to the same period in 2025. Net sales for the nine-month periods ended September 30, 2026, increased 8% in both U.S. dollars and local currency compared to the same period of 2025. The sales increases for the three- and nine-month periods were due to higher sales of first-aid products.

 

Gross margin was 45.3% in the third quarter of 2026 versus 39.1% in the comparable period last year. Gross margin for the third quarter included a benefit of approximately 690 basis points from the tariff refund partially offset by approximately 310 basis points related to the DMT facility closure costs. Gross margin was 42.6% for the nine-month period ended September 30, 2026, compared to 39.8% for the same period in 2025. Gross margin for the nine months ended September 30, 2026 included a benefit of approximately 230 basis points from the tariff refund partially offset by approximately 105 basis points related to the DMT closure costs. Excluding the impact of the tariff refund and DMT closure costs, gross margin remained above prior-year levels primarily driven by the inclusion of the new My Medic direct to consumer business.

 

The Company’s bank debt less cash as of September 30, 2026 was $29.7 million compared to $23.1 million as of September 30, 2025. During the twelve-month period ended September 30, 2026, the Company paid approximately $14.5 million for the acquisition of the assets of My Medic ($18.6 million purchase price less $4.1 million of holdbacks), distributed approximately $2.4 million in dividends on its common stock and purchased the cutting and sharpening line of products in Germany for approximately $1.6 million. During the same period, the Company generated approximately $13.8 million in free cash flow, including $6.0 million in tariff refunds.

Conference Call and Webcast Information

Acme United will hold a conference call to discuss its quarterly results, which will be broadcast on Tuesday, October 27, 2026, at 12:00 p.m. ET. To listen or participate in a

3

 


Ex 99.1

question-and-answer session, dial 877-407-0784. International callers may dial 201-689-8560. The confirmation code is 13763109. You may access the live webcast of the conference call through the Investor Relations section of the Company’s website, www.acmeunited.com. A replay may be accessed under Investor Relations, Audio Archives.

 

About Acme United

ACME UNITED CORPORATION is a leading worldwide supplier of innovative safety solutions and cutting technology to the school, home, office, hardware, sporting goods and industrial markets. Its leading brands include First Aid Only®, First Aid Central®, PhysiciansCare®, Pac-Kit®, Spill Magic®, Westcott®, Clauss®, DMT®, Med-Nap®, Elite First Aid® and My Medic®. For more information, visit www.acmeunited.com.

 

Forward Looking Statements

 

The Company may from time to time make written or oral “forward-looking statements” including statements contained in this release and in other communications by the Company, which are made in good faith pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our beliefs as well as assumptions made by and information currently available to us. When used therein this document, words like “may,” “might,” “will,” “expect,” “anticipate,” “believe,” “potential,” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from our current expectations.

 

Forward-looking statements in this release, including without limitation, statements related to the Company’s plans, strategies, objectives, expectations, intentions and adequacy of resources, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties that may impact the Company’s business, operations and financial results.

 

These risks and uncertainties include, without limitation, the following: (i) changes in the Company’s plans, strategies, objectives, expectations and intentions, which may be

4

 


Ex 99.1

made at any time at the discretion of the Company; (ii) the impact of volatility in global economic conditions, including the impact on the Company’s suppliers and customers; (iii) international trade policies of the United States or foreign governments and their impact on demand for our products and our competitive position, including the imposition of new tariffs, changes in existing tariff rates or the threat of any such action; (iv) the continuing adverse impact of inflation, including product costs, and interest rates; (v) potential adverse effects on the Company, its customers, and suppliers resulting from the conflicts in Ukraine and the Middle East; (vi) additional disruptions in the Company’s supply chains, whether caused by pandemics, natural disasters, including trucker shortages, strikes, port closures or otherwise; (vii) labor related costs the Company has and may continue to incur, including costs of acquiring and training new employees and rising wages and benefits; (viii) currency fluctuations; (ix) the Company’s ability to effectively manage its inventory in a rapidly changing business environment; (x) changes in client needs and consumer spending habits; (xi) the impact of competition; (xii) the impact of technological changes including, specifically, the growth of online marketing and sales activity; and (xiii) the Company’s ability to manage its growth effectively, including its ability to successfully integrate any business it might acquire; and (xiv) other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission.

 

# # #

 

 

 

 

 

 

 

 

 

 

 

5

 


Ex 99.1

 

 

 

ACME UNITED CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

 

THIRD QUARTER REPORT 2026

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Three Months Ended

 

Amounts in 000's except per share data

 

September 30, 2026

 

 

 

September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

 

58,013

 

 

 $

 

49,063

 

Cost of goods sold

 

 

31,713

 

 

 

 

29,868

 

Gross profit

 

 

26,300

 

 

 

 

19,195

 

Selling, general and administrative expenses

 

 

21,837

 

 

 

 

16,188

 

Operating income

 

 

4,463

 

 

 

 

3,007

 

Net interest expense

 

 

594

 

 

 

 

422

 

Other expense, net

 

 

6

 

 

 

 

146

 

Income before income tax expense

 

 

3,863

 

 

 

 

2,439

 

Income tax expense

 

 

428

 

 

 

 

536

 

Net income

$

 

3,435

 

 

 $

 

1,903

 

 

 

 

 

 

 

 

 

Shares outstanding - basic

 

 

3,909

 

 

 

 

3,802

 

Shares outstanding - diluted

 

 

4,296

 

 

 

 

4,168

 

 

 

 

 

 

 

 

 

Earnings per share - basic

$

 

0.88

 

 

$

 

0.50

 

Earnings per share - diluted

 

 

0.80

 

 

 

 

0.46

 

 

 

 

 

 

 

 

 

 

 

 

6

 


Ex 99.1

ACME UNITED CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

 

THIRD QUARTER REPORT 2026

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

Nine Months Ended

 

Amounts in 000's except per share data

 

September 30, 2026

 

 

 

September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

 

173,030

 

 

 $

 

149,018

 

Cost of goods sold

 

 

99,257

 

 

 

 

89,756

 

Gross profit

 

 

73,773

 

 

 

 

59,262

 

Selling, general and administrative expenses

 

 

60,736

 

 

 

 

47,438

 

Operating income

 

 

13,037

 

 

 

 

11,824

 

Net interest expense

 

 

1,613

 

 

 

 

1,222

 

Other expense (income), net

 

 

17

 

 

 

 

(44

)

Income before income tax expense

 

 

11,407

 

 

 

 

10,646

 

Income tax expense

 

 

1,938

 

 

 

 

2,338

 

Net income

$

 

9,469

 

 

 $

 

8,308

 

 

 

 

 

 

 

 

 

Shares outstanding - basic

 

 

3,851

 

 

 

 

3,781

 

Shares outstanding - diluted

 

 

4,134

 

 

 

 

4,091

 

 

 

 

 

 

 

 

 

Earnings per share - basic

$

 

2.46

 

 

$

 

2.20

 

Earnings per share - diluted

 

 

2.29

 

 

 

 

2.03

 

 

 

 

 

 

 

 

 

 

 

7

 


Ex 99.1

ACME UNITED CORPORATION

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

THIRD QUARTER REPORT 2026

 

(Unaudited)

 

 

 

 

 

 

 

 

 

Amounts in $000's

 

 

 

 

 

 

 

 

 

September 30, 2026

 

 

 

September 30, 2025

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

 

7,944

 

 

$

 

5,146

 

Accounts receivable, net

 

 

36,193

 

 

 

 

30,034

 

Inventories

 

 

69,034

 

 

 

 

60,163

 

Prepaid expenses and other current assets

 

 

3,718

 

 

 

 

3,363

 

Total current assets

 

 

116,889

 

 

 

 

98,706

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

39,432

 

 

 

 

38,691

 

 

 

 

 

 

 

 

 

Operating lease right of use asset

 

 

9,179

 

 

 

 

7,261

 

Intangible assets, less accumulated amortization

 

 

32,451

 

 

 

 

18,476

 

Goodwill

 

 

9,908

 

 

 

 

9,908

 

Total assets

$

 

207,859

 

 

$

 

173,042

 

 

 

 

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

 

10,304

 

 

$

 

6,488

 

Operating lease liability - short term

 

 

1,189

 

 

 

 

1,427

 

Mortgage payable - short term

 

 

467

 

 

 

 

450

 

Other current liabilities

 

 

18,057

 

 

 

 

13,722

 

Total current liabilities

 

 

30,017

 

 

 

 

22,087

 

 

 

 

 

 

 

 

 

Long-term debt

 

 

28,090

 

 

 

 

18,255

 

Mortgage payable - long term

 

 

9,125

 

 

 

 

9,556

 

Operating lease liability - long term

 

 

8,081

 

 

 

 

5,900

 

Deferred income taxes

 

 

3,685

 

 

 

 

1,465

 

Other non-current liabilities

 

 

3,995

 

 

 

 

15

 

Total liabilities

 

 

82,993

 

 

 

 

57,278

 

Total stockholders' equity

 

 

124,866

 

 

 

 

115,764

 

Total liabilities and stockholders' equity

$

 

207,859

 

 

$

 

173,042

 

 

 

 

 

 

 

 

 

 

8

 


Filing Exhibits & Attachments

2 documents

Keep reading